NCT03899155 2026-04-01
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
Clinical Trials
12 trialsNCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05502315 2026-01-23
CANOPY
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT04116541 2025-11-21
MegaMOST
Centre Leon Berard
Phase 2 Recruiting
NCT03611595 2025-08-28
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
University of California, San Diego
Phase 1 Recruiting
NCT01979393 2025-08-01
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT05289856 2024-03-07
Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)
Johannes Gutenberg University Mainz
Phase 2 Unknown
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT01428219 2017-12-12
Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT01553656 2015-08-20
Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
Exelixis
Phase 1 Completed
NCT01018745 2011-01-07
Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan
Bristol-Myers Squibb
Phase 1 Completed